ISSN: 0976-7126
Gupta *et al.*, 16(10):7-20, 2025

International Journal of Pharmacy & Life Sciences
Open Access to Researcher

Digital Therapeutics: regulatory Challenges for AI-based Healthcare Solutions

Gourav Gupta, Akanksha Dwivedi*and G.N. Darwhekar

Acropolis Institute of Pharmaceutical Education and Research, Indore, (M.P.) - India

Article info

Received: 29/08/2025

Revised: 30/09/2025

Accepted: 05/10/2025

www.ijplsjournal.com

Abstract

Modern healthcare is changing as a result of the incorporation of Artificial Intelligence (AI) into digital treatments, which provide evidence-based, scalable and customized software based interventions. These AI-powered technologies have enormous promise for improving patient adherence, controlling chronic illnesses, and providing immediate clinical assistance. But because they are developing faster than current regulatory frameworks, there is a serious supervision, validation, and accountability vacuum. This review examines the intricate regulatory concerns surrounding AI-based digital therapies, such as those pertaining to data protection, real-world proof requirements, algorithm transparency, and software categorization. It also looks at how inconsistent regulatory requirements are throughout the world and how hard it is to stay up with AI systems that are flexible and always learning from fresh data.

This article emphasizes the essential need for a unified and flexible regulatory environment that strikes a balance between innovation, patient safety and ethical responsibility through a multidisciplinary perspective. The information offered is intended to help developers, regulators and healthcare stakeholders create governance frameworks that can facilitate the safe and efficient application of AI in therapeutic contexts.

Keywords: Artificial Intelligence (AI), digital, regulatory, real-world, therapeutic.

Introduction

Digital Therapeutics (DTx), defined as evidence-based therapeutic interventions delivered through high-quality software, are rapidly transforming healthcare. These innovative solutions, increasingly powered by Artificial Intelligence (AI) and Machine Learning (ML) algorithms, promise to personalize care, improve patient outcomes, and enhance healthcare system efficiency. From AI-driven tools for chronic disease management to ML models predicting disease progression, DTx hold immense potential. However, this rapid technological advancement introduces a complex set of regulatory challenges that existing frameworks are struggling to address[1].

One of the primary hurdles lies in the adaptive nature of AI-based DTx. Unlike traditional medical devices with static functionalities, AI algorithms can learn and evolve from real-world data, continuously improving their performance. This inherent adaptability clashes with conventional "snapshot" approval processes, which typically require re-authorization for any significant modification. Regulators, therefore, face the challenge of developing adaptive frameworks that ensure ongoing safety and effectiveness without stifling the iterative improvement characteristic of AI [1].

***Corresponding Author**
E.mail: akd.pharma@gmail.com

ISSN: 0976-7126
Gupta *et al.*, 16(10):7-20, 2025

The US FDA, for instance, has acknowledged this by exploring "Predetermined Change Control Plans" for AI/ML-based Software as a Medical Device (SaMD) [2].

Furthermore, the "black box" nature of some advanced AI models, where the decision-making process is not readily transparent, poses a significant regulatory concern. Regulators need to understand how these algorithms arrive at their conclusions to assess potential biases, ensure fairness, and establish accountability. The quality and representativeness of the data used to train these AI models are also critical, as biased datasets can lead to discriminatory outcomes and exacerbate health disparities [3]. Ensuring data privacy, security, and integrity is paramount given the sensitive health information these solutions handle.

The classification of AI-based DTx also presents ambiguity. Are they simply "software as a medical device" (SaMD), or do they necessitate a new category that accounts for their unique characteristics? This lack of clear categorization can lead to fragmented oversight. Jurisdictions like the EU, with its AI Act, are attempting to categorize AI systems in healthcare as high-risk, imposing stringent requirements on data governance, transparency, and human oversight [4]. In India, the regulatory landscape for digital health and AI is still evolving, with existing IT laws and data protection acts providing partial coverage, and ongoing efforts to develop more specific guidelines [5]. Navigating these varied and evolving regulatory environments requires a collaborative effort to ensure safe and effective AI-driven healthcare solutions.

AI'S Effects on Healthcare

Artificial Intelligence (AI) is rapidly reshaping the landscape of healthcare, offering unprecedented opportunities to enhance efficiency, personalize care, and improve patient outcomes. Its influence extends across various facets of the healthcare ecosystem, from fundamental research to direct patient interventions.

At its core, AI in healthcare leverages sophisticated algorithms, machine learning (ML), and deep learning techniques to analyze vast and complex datasets. These datasets include electronic health records (EHRs), medical images (X-rays, MRIs, CT scans), genomic data, real-time physiological sensor data, and even unstructured text from clinical notes. By identifying intricate patterns and correlations that might be imperceptible to human analysis, AI models can generate insights, make predictions, and support decision-making [6].The foundational strength of AI lies in its ability to process massive volumes of diverse data at speeds far exceeding human capacity, learning and adapting over time to refine its performance.

Applications in medicine



Fig.1. The AI impact on Future Healthcare System

The applications of AI in medicine are broad and continually expanding, demonstrating its transformative potential:

Diagnostic Assistance: AI excels in interpreting medical images, such as X-rays for lung conditions, MRIs for neurological disorders, and CT scans for cancer detection. AI algorithms can identify subtle anomalies, often with higher accuracy and speed than human clinicians, aiding in earlier and more precise diagnoses [7]. This capability significantly reduces diagnostic errors and streamlines workflows in specialties like radiology and pathology.

Drug Discovery and Development: AI is accelerating the notoriously lengthy and expensive process of drug discovery. It can predict potential drug candidates, simulate molecular interactions, identify disease targets,

ISSN: 0976-7126
Gupta *et al.*, 16(10):7-20, 2025

and optimize the design of clinical trials, thereby reducing time-to-market and development costs. AI-driven platforms can analyze vast chemical libraries to pinpoint compounds with desired therapeutic properties, or even design novel molecules from scratch [8].

Personalized Medicine: Moving beyond the "one-size-fits-all" approach, AI enables truly personalized medicine. By integrating a patient's genetic makeup, lifestyle data, environmental factors, and medical history, AI can predict individual responses to treatments, identify optimal drug dosages, and tailor preventive strategies. This allows for highly customized care plans that maximize efficacy and minimize adverse effects [9].

Clinical Decision Support (CDS) Systems: AI-powered CDS systems provide healthcare professionals with evidence-based insights at the point of care. These systems can flag potential drug interactions, suggest appropriate diagnostic tests, recommend treatment protocols based on patient-specific data, and even predict the risk of disease progression or complications. They serve as intelligent assistants, augmenting clinicians' capabilities and improving decision quality [6].

Robotic Surgery: AI is enhancing robotic surgical systems, improving precision, control, and efficiency during complex procedures. AI can provide real-time guidance to surgeons, analyze surgical data to identify optimal techniques, and even automate certain repetitive tasks, leading to safer and more effective interventions [10].

Public Health and Disease Surveillance: AI can analyze epidemiological data, social media trends, and environmental factors to predict disease outbreaks, track the spread of infectious diseases, and inform public health interventions. This proactive capability allows for more timely and targeted responses to health crises [11].

Administrative Efficiency: Beyond direct patient care, AI streamlines administrative tasks, such as medical coding, patient scheduling, billing, and electronic health record management. This reduces the administrative burden on healthcare providers, freeing up time for direct patient interaction and improving overall operational efficiency [7].

In essence, AI's profound effect on healthcare stems from its ability to process, analyze, and learn from vast datasets, leading to advancements in precision, personalization, and efficiency across nearly every aspect of the medical field. However, this transformative power also introduces significant regulatory, ethical, and societal challenges that necessitate careful consideration and robust frameworks to ensure its safe, fair, and equitable deployment.

Table 1: Applications of AI in Medicine

Application Area	Description and Impact
Diagnostic Assistance	AI interprets medical images (X-rays, MRIs, CT scans) with high speed and accuracy, identifying subtle anomalies to support early, precise diagnoses and reduce diagnostic errors.
Drug Discovery and Development	AI accelerates drug development by predicting candidates, simulating molecular interactions, and optimizing clinical trial designs, lowering costs and time to market.
Personalized Medicine	AI tailors treatments by analyzing genetic, environmental, and lifestyle data to predict drug responses, adjust dosages, and design custom preventive care strategies.
Clinical Decision Support (CDS)	AI-powered CDS tools provide real-time, evidence-based recommendations to clinicians, flagging drug interactions, guiding test selection, and predicting disease risks.
Robotic Surgery	AI enhances robotic surgical precision, offering real-time decision support, automating tasks, and improving outcomes in complex procedures.

Public Health & Disease Surveillance	AI analyzes health trends, environmental data, and social signals to forecast disease outbreaks and inform timely public health interventions.
Administrative Efficiency	AI automates medical coding, scheduling, billing, and record management, reducing clinician workload and enhancing healthcare system efficiency.

AI Approaches in Healthcare Solutions

The convergence of Artificial Intelligence (AI) and healthcare is ushering in a new era of medical innovation, with Digital Therapeutics (DTx) at the forefront. DTx are evidence-based therapeutic interventions delivered through software programs to prevent, manage, or treat a medical disorder or disease. While the potential benefits are immense, including improved diagnoses, personalized treatments, and enhanced patient engagement, the regulatory landscape struggles to keep pace with the rapid advancements in AI-driven healthcare solutions.AI's applications in healthcare are diverse and rapidly expanding. Machine learning algorithms, a core component of AI, are being leveraged for:

Improved Medical Diagnosis: AI can analyze vast amounts of medical imaging data (e.g., X-rays, MRIs, CT scans) to detect subtle anomalies that might be missed by the human eye, aiding in early disease detection and diagnosis of conditions like fractures or even certain diseases before symptoms appear. This can lead to more accurate and faster diagnostic processes[12].

Drug Discovery and Development: AI accelerates drug discovery by predicting potential drug candidates, analyzing molecular structures, and identifying suitable participants for clinical trials. This significantly reduces the time and cost associated with bringing new therapies to market[13].

Personalized Treatment Plans: By analyzing individual patient data, including genetic information, medical history, and lifestyle factors, AI can help tailor treatment plans for optimal efficacy and minimized side effects, moving towards true precision medicine[14].

Remote Monitoring and Patient Engagement: AI-powered digital therapeutics and remote monitoring systems can continuously track patient health, provide real-time feedback, and offer personalized guidance, leading to better adherence to treatment plans and improved long-term outcomes for chronic conditions[15].

Operational Efficiency: AI can streamline administrative tasks, manage healthcare data, and optimize resource allocation within healthcare systems, freeing up human professionals to focus on direct patient care[16].

Table 2:AI Approaches in Healthcare Solutions

AI Approach	Description and Impact
Improved Medical Diagnosis	Uses AI to analyze medical imaging (X-rays, MRIs, CT scans) for early and accurate detection of conditions, reducing diagnostic errors and accelerating treatment.
Drug Discovery and Development	AI identifies promising drug candidates, predicts molecular interactions, and selects clinical trial participants — reducing time and R&D costs.
Personalized Treatment Plans	Integrates genetic, clinical, and lifestyle data to tailor treatments, enhancing outcomes and reducing adverse effects — a move toward precision medicine.
Remote Monitoring & Patient Engagement	Enables continuous health tracking, real-time feedback, and customized interventions, especially for chronic conditions, improving adherence and outcomes.
Operational Efficiency	Automates routine tasks, enhances data management, and optimizes resource use, allowing clinicians to concentrate more on patient-centered care.

Regulatory Challenges

The integration of Artificial Intelligence (AI) into healthcare, particularly within the burgeoning field of Digital Therapeutics (DTx), promises transformative advancements in patient care, disease management, and public health. DTx, defined as evidence-based therapeutic interventions driven by software to prevent, manage, or treat a medical disorder or disease, stands to benefit immensely from AI's analytical power. However, this revolutionary potential is tempered by a complex and evolving regulatory landscape that poses significant challenges for the safe, ethical, and effective deployment of AI-based healthcare solutions.

The Rise of Digital Therapeutics and AI

Digital Therapeutics leverage software programs to deliver medical interventions directly to patients, often via mobile applications, web platforms, or wearable devices. Unlike general wellness apps, DTx solutions are clinically validated and require rigorous regulatory approvals. The incorporation of AI within DTx amplifies their capabilities, enabling personalized treatment plans, real-time data analysis, predictive analytics for early disease detection, and adaptive interventions that learn and evolve with user interaction. For instance, AI can power algorithms that tailor cognitive behavioral therapy modules for mental health DTx, analyze glucose levels for diabetes management, or predict patient adherence to medication[17].

Regulatory Challenges for AI-Based Healthcare Solutions

The unique characteristics of AI, especially its adaptive and opaque nature, introduce a host of regulatory hurdles that traditional medical device frameworks were not designed to address.

Data Privacy and Security: AI models thrive on vast amounts of data, and in healthcare, this data is inherently sensitive patient health information. Regulations like GDPR in Europe and HIPAA in the US impose strict requirements for data privacy, consent, and security. AI systems must ensure robust data protection measures, prevent unauthorized access, and maintain patient confidentiality. The challenge is magnified by the need for large, high-quality datasets to train AI models effectively, while simultaneously adhering to principles of data minimization and purpose limitation. Ensuring explicit patient consent for data utilization, especially when data might be used for ongoing AI model improvement, is a persistent and complex issue[18].

Algorithmic Transparency and Explainability (the "Black Box" Problem): Many advanced AI models, particularly deep learning algorithms, operate as "black boxes," meaning their decision-making processes are difficult to understand or explain. In healthcare, where decisions can have life-or-death consequences, clinicians and patients need to trust and understand how an AI arrived at a particular recommendation or diagnosis. Regulatory frameworks are increasingly pushing for algorithmic transparency, requiring developers to provide clear explanations of AI functions and decision-making. This demand for explainability often conflicts with the inherent complexity of sophisticated AI, creating a significant technical and regulatory challenge[19].

Bias and Fairness: AI models are only as unbiased as the data they are trained on. If training data is not diverse and representative of all patient populations (e.g., lacking data from certain racial, ethnic, gender, or socioeconomic groups), the AI system can perpetuate and even amplify existing health disparities. This algorithmic bias can lead to unequal or inaccurate care for certain patient demographics. Regulators are grappling with how to mandate fairness-aware design, inclusive dataset collection, and regular AI model audits to identify and mitigate bias throughout the AI lifecycle[20].

Evolving Nature of Adaptive AI (Software as a Medical Device - SaMD):

Unlike traditional software, some AI algorithms, particularly those employing machine learning, can continuously learn and adapt from real-world data after deployment. This adaptive nature challenges the traditional regulatory model of pre-market approval, which often assumes a static product. Regulators like the FDA are developing new approaches, such as the "Predetermined Change Control Plan," which allows manufacturers to define the boundaries of anticipated algorithm changes in advance, reducing the need for constant re-submissions. However, defining and overseeing these "pre-specified" changes for truly adaptive AI remains a significant regulatory frontier[21].

Clinical Validation and Efficacy: Digital Therapeutics, by definition, must demonstrate clinical efficacy. For AI-based DTx, this means proving that the AI-driven interventions lead to improved patient outcomes. This often requires rigorous clinical trials, which can be time-consuming and expensive. The dynamic nature of AI further complicates validation, as performance may shift over time. Regulators need robust methodologies for evaluating the safety and effectiveness of AI-driven interventions, including continuous monitoring and post-market surveillance[22].

Liability and Accountability: When an AI-driven DTx makes an error that harms a patient, determining liability becomes a complex legal question. Is it the developer, the healthcare provider, the institution, or a combination? Traditional legal frameworks for medical malpractice may not adequately address AI-generated errors, especially when the AI's decision-making process is opaque. Clear guidelines on accountability are essential for fostering trust and encouraging the adoption of AI in healthcare[23].

Regulatory Harmonization and Fragmentation: The global nature of technology development means that AI-based DTx developed in one country may be deployed worldwide. However, regulatory frameworks vary significantly across jurisdictions (e.g., FDA in the US, EMA in Europe, MHRA in the UK, and evolving frameworks in India). This fragmentation creates a challenging environment for developers, requiring them to navigate multiple, sometimes conflicting, sets of requirements. Efforts towards international regulatory harmonization, such as the IMDRF's work on SaMD, are crucial but remain a long-term endeavor. The EU AI Act, for instance, categorizes AI systems in healthcare as "high-risk," subjecting them to stringent requirements, which will impact medical device manufacturers globally[24].

Integration into Clinical Workflow and Clinician Acceptance: Beyond direct regulation, a significant challenge lies in integrating AI-based DTx into existing healthcare systems and gaining acceptance from clinicians. Concerns about trust, reliability, potential job displacement, and the need for new training can hinder adoption. Regulatory bodies may need to consider how to facilitate this integration, ensuring that AI tools are user-friendly, provide actionable insights, and are adequately supported by healthcare professionals[25].

Table 3: Regulatory Challenges for AI-Based Healthcare Solutions

Category	Challenge	Description
Data Privacy & Security	Patient data protection	Strict compliance with evolving data protection laws (e.g., HIPAA, GDPR) is crucial for AI, demanding meticulous handling of sensitive health data, managing cross-border flows, and robust anonymization to prevent re-identification.
Bias & Fairness	Algorithmic bias	Addressing inherent inequalities or systemic discrimination from AI algorithms due to training data biases, demographic underrepresentation, or design flaws is crucial. Such biases can lead to inaccurate diagnoses, suboptimal treatment, or inequitable care.
Transparency	Explainability of AI decisions	The 'black-box' nature of many AI models complicates understanding their reasoning for clinicians, patients, and regulators. This lack of interpretability impacts trust, hinders validation, and complicates accountability, necessitating Explainable AI (XAI).
Validation & Standards	Clinical validation	A pressing need exists for globally standardized frameworks to rigorously test and validate AI tools across diverse clinical settings and real-world data environments, as current methods often fail to account

		for variability.
Liability	Legal responsibility	Clarifying accountability is complex. When an AI system causes patient harm, determining legal responsibility among the developer, manufacturer, healthcare provider, or clinician is often ambiguous, creating significant legal uncertainties.
Regulatory Approval	Approval process	Existing regulatory frameworks (e.g., FDA, EMA), designed for static medical devices, struggle to evaluate and approve adaptive AI models that continuously learn and evolve post-deployment, challenging traditional pre-market processes.
Interoperability	Integration with existing systems	Seamless AI integration with fragmented, often outdated healthcare IT infrastructure is a major operational challenge. This stems from data silos, disparate EHR systems, and a lack of standardized data formats.
Ethics & Consent	Informed consent for AI use	Genuinely informed patient consent for AI use is critical, requiring clear communication about AI's role in diagnosis/treatment, its benefits/limitations, probabilistic outputs, and human oversight to empower patient autonomy.
Continuous Monitoring	Post-deployment performance and updates	Robust post-market surveillance is necessary for dynamic AI tools. This entails continuous oversight of AI performance to detect 'model drift', manage routine updates, and implement rapid re-validation and communication.

AI-Enabled Personalized Oncology Approaches

Artificial intelligence (AI) is rapidly transforming oncology, shifting the paradigm from standardized treatments to highly personalized approaches tailored to each cancer patient's unique biological and clinical profile. This move towards "precision oncology" promises more effective therapies, fewer side effects, and ultimately, improved patient outcomes.

AI-Enabled Personalized Oncology Approaches

AI's transformative power in personalized oncology is evident across several key areas. It excels at **multi-omics integration and analysis**, deciphering the unique molecular signatures of each tumor by combining genomic, transcriptomic, proteomic, metabolomic, and microbiomic data with clinical information. This comprehensive understanding allows for a more precise identification of tumor drivers and prediction of behavior. Furthermore, AI is crucial for **predicting treatment response and resistance**, using large datasets to forecast how patients will react to various therapies, thereby optimizing treatment selection and avoiding ineffective interventions. The technology also significantly accelerates **biomarker discovery and validation**, identifying novel indicators for early detection, treatment monitoring, and personalized drug selection. In the realm of patient care, AI-powered solutions enable **real-time monitoring and adaptive therapy**, providing continuous support, tracking symptoms, and making timely adjustments to treatment plans. AI also plays a vital role in **optimizing radiation therapy and surgery**, precisely targeting tumors and guiding complex procedures for greater accuracy. Finally, AI is revolutionizing **drug discovery and repurposing** by identifying potential drug targets, predicting drug efficacy and toxicity, and even suggesting new applications for existing medications.

ISSN: 0976-7126
Gupta *et al.*, 16(10):7-20, 2025



Fig. 1: The current approaches for assay- and image-based companion/complementary diagnostics (CDx, TDx, cDx) and the emerging technologies for AI-based and information-integrative approaches. iTDx - image-based TDX.

Table 4: AI-Enabled Personalized Oncology Approaches

AI Application Area	Description
Multi-Omics Integration and Analysis	AI integrates genomics, transcriptomics, proteomics, and more with clinical data to provide a comprehensive molecular view of a patient's cancer, helping identify unique tumor drivers.
Predicting Treatment Response and Resistance	AI models predict how patients will respond to therapies by associating molecular profiles with treatment outcomes, aiding in selecting effective and less toxic treatment strategies.
Biomarker Discovery and Validation	AI helps discover and validate biomarkers for early detection, prognosis, and treatment response by analyzing complex biological data that traditional methods may overlook.
Real-time Monitoring and Adaptive Therapy	AI-powered DTx tools monitor symptoms, adherence, and patient data in real-time, enabling timely adjustments in care and providing personalized behavioral and clinical interventions.
Optimizing Radiation Therapy and Surgery	AI enhances precision in radiation planning and surgical navigation by analyzing imaging data and anatomical structures, reducing harm to healthy tissue and improving outcomes.
Accelerating Drug Discovery and Repurposing	AI accelerates drug discovery by identifying new targets, predicting compound effectiveness and toxicity, and suggesting existing drugs for new cancer applications based on molecular matching.

By bringing together diverse data sources and applying advanced analytical capabilities, AI is paving the way for a new era in oncology where treatments are precisely matched to the individual, maximizing effectiveness and minimizing harm. This personalization holds immense promise for improving patient outcomes and quality of life in the fight against cancer.

Other Challenges

The rapid evolution of Artificial Intelligence (AI) is fundamentally reshaping the healthcare landscape, with profound implications for Digital Therapeutics (DTx). DTx, as evidence-based software-driven interventions, are increasingly leveraging AI to deliver personalized and effective care. However, this integration introduces a complex interplay of regulatory challenges, particularly concerning the foundational elements of medical practice: the doctor-patient relationship, the process of clinical decision-making, and the management of health data[32].

The Interaction Between a Doctor and Patient

The traditional doctor-patient interaction, built on trust, empathy, and shared decision-making, faces significant transformation with the introduction of AI-powered solutions.

ISSN: 0976-7126
Gupta *et al.*, 16(10):7-20, 2025

Regulatory Challenges: However, AI's role in this interaction introduces several regulatory and ethical dilemmas:

Erosion of Trust and Human Connection: A primary concern is that over-reliance on AI might depersonalize care, leading to a perception that technology is replacing human empathy. If AI recommendations are opaque or clinicians struggle to explain AI's reasoning, it can erode patient trust in both the technology and the healthcare provider. Regulators face the challenge of ensuring AI solutions are designed to augment, not diminish, the human element of care[32].

Information Overload and Misinterpretation: AI can generate vast amounts of data and complex insights. Both doctors and patients may struggle to interpret this information accurately without proper training or user-friendly interfaces. Regulatory bodies need to consider mandating clear, understandable presentation of AI outputs within DTx to prevent misinterpretation and ensure informed decision-making[34].

Informed Consent for AI-Influenced Care: As AI's influence grows in diagnostics and treatment planning, obtaining genuinely informed consent becomes more intricate. Patients need to understand the extent to which AI is involved in their care, its limitations, and the implications for their data. Regulatory guidelines must evolve to address what constitutes adequate consent in an AI-augmented healthcare environment[35].

Ethical Boundaries of "AI as Advisor": When AI acts as a significant "advisor" in the consultation, ethical questions arise regarding the physician's autonomy and fiduciary duty. How do clinicians maintain ultimate responsibility and ensure they are not merely "rubber-stamping" algorithmic recommendations? Regulatory frameworks must define clear lines of responsibility and promote AI as a tool for augmentation, with human oversight as paramount[35].

Clinical Decision-Making Enabled by AI

AI's potential to revolutionize clinical decision-making, from diagnosis to treatment planning, is immense. It promises to analyze vast datasets, identify subtle patterns, and provide personalized insights far beyond human cognitive capabilities[37].

Regulatory Challenges: The integration of AI into such critical processes brings forth substantial regulatory hurdles:

Augmentation vs. Automation and Human Oversight: A core regulatory distinction lies between AI that serves as clinical decision *support* (augmenting human judgment) and AI that *automates* decisions. Most global regulators, including the FDA, primarily approve AI for augmentation, emphasizing the necessity of robust human oversight. The challenge is defining the appropriate level of human intervention, especially for highly autonomous AI systems. Regulatory frameworks must articulate when AI's outputs are merely informational and when they become direct medical device functions requiring stricter scrutiny[37].

Accountability and Liability: When an AI contributes to a clinical decision that leads to patient harm, determining legal liability becomes incredibly complex. Is the developer accountable for the algorithm's design? The clinician for its application? The hospital for its implementation? Existing medical malpractice laws often do not adequately address this shared responsibility in an AI-driven scenario. Regulators are grappling with establishing clear legal precedents and guidelines to assign accountability, which is crucial for fostering trust and ensuring patient recourse[36].

Algorithmic Bias and Fairness: AI models are susceptible to inheriting and even amplifying biases present in their training data. If datasets are unrepresentative of diverse patient populations (e.g., lacking data from certain racial, ethnic, or socioeconomic groups), the AI's recommendations may be inaccurate, less effective, or even harmful for those underserved groups. This can exacerbate existing health disparities. Regulators are under pressure to mandate rigorous data diversity requirements, comprehensive bias detection methodologies, and ongoing fairness audits throughout the AI lifecycle[35].

Explainability and Transparency (The "Black Box" Problem): Many advanced AI models, particularly deep neural networks, operate as "black boxes," meaning their internal decision-making processes are opaque. Clinicians need to understand *why* an AI provided a specific recommendation to critically evaluate it and justify decisions to patients. Regulatory bodies are

increasingly pushing for explainable AI (XAI) to ensure transparency, allowing for verification of AI's rationale and building clinician trust. This often conflicts with the inherent complexity of high-performing AI[36].

Dynamic Adaptation and Revalidation: AI systems that continuously learn and adapt from real-world data post-deployment (common in personalized oncology, for example) pose a unique challenge to traditional pre-market approval processes. Regulators like the FDA are developing new frameworks, such as the "Predetermined Change Control Plan" for Software as a Medical Device (SaMD), to manage these adaptive algorithms. However, defining the scope of permissible changes and ensuring continuous safety and efficacy monitoring for truly adaptive AI remains a frontier of regulatory science[37].

Records of Health Data

The backbone of AI in healthcare is data. The unprecedented volume, velocity, and variety of health data required by AI solutions bring significant challenges related to privacy, security, quality, and governance[39].

Regulatory Challenges: The vast and sensitive nature of health data used by AI necessitates stringent regulatory oversight:

Data Privacy and Consent: AI models thrive on vast amounts of patient health information (PHI), including highly sensitive genomic, lifestyle, and clinical data. Navigating stringent privacy regulations like GDPR (Europe), HIPAA (US), and emerging data protection laws globally is paramount. Key challenges include:

Scope of Consent: Obtaining specific and informed consent for complex data uses, especially when data might be utilized for continuous AI model improvement or shared with multiple entities (e.g., cloud providers, research partners), is intricate.

De-identification/Anonymization: Ensuring that data is truly de-identified or anonymized to prevent re-identification, particularly with granular and diverse datasets, is a persistent technical and regulatory challenge.

Data Minimization: Adhering to the principle of collecting only necessary data for a specific purpose, while still ensuring sufficient data for robust AI training, is a delicate balance[39].

Data Security and Cybersecurity: Healthcare data is a prime target for cybercriminals. AI systems, with their complex architecture, interconnectedness, and reliance on large datasets, significantly expand the attack surface. Regulatory bodies are intensifying demands for:

Robust Cybersecurity Measures: Mandating advanced encryption, access controls, threat detection systems, and regular security audits for AI-powered DTx and associated data infrastructure.

Breach Notification: Clear protocols for reporting data breaches and ensuring patient notification in a timely manner.

Data Integrity: Protecting the integrity of training and operational data from malicious manipulation (e.g., data poisoning attacks) is crucial, as corrupted data can lead to erroneous AI decisions with severe patient consequences[40].

Data Quality and Interoperability: AI models are only as reliable as the data they consume.

Poor Data Quality: Electronic Health Records (EHRs) often suffer from issues like incompleteness, inconsistencies, free-text inaccuracies, and varying coding practices. AI models trained on such "noisy" data will produce unreliable outputs. Regulators may need to push for higher standards of data entry and curation.

Lack of Interoperability: Healthcare data remains highly siloed across different providers, systems, and geographies. This fragmentation hinders the aggregation of diverse, high-quality datasets necessary for training robust and generalizable AI models. Regulatory efforts to promote standardized data formats (e.g., HL7 FHIR) and interoperability frameworks are crucial but face significant implementation hurdles[41].

ISSN: 0976-7126
Gupta *et al.*, 16(10):7-20, 2025

Table 5: Other Challenges

Section	Opportunities	Regulatory Challenges
Doctor-Patient Interaction	• Empowering patients with personalized insights and education • Streamlining communication via automation (e.g., charting) • Continuous personalized support outside clinics	• Risk of depersonalization and erosion of empathy • Data overload and misinterpretation without proper interfaces • Complexity in achieving informed consent for AI usage • Ethical concerns on physician autonomy and AI's advisory role
Clinical Decision-Making	• Enhanced diagnostic accuracy through imaging and data analysis • Personalized treatment via AI-driven predictive analytics • Risk stratification for proactive care • Automation of repetitive clinical/admin tasks	• Augmentation vs automation — ensuring proper human oversight • Ambiguity in liability for AI-related errors • Risk of algorithmic bias harming underrepresented groups • Opaqueness of AI (black box problem) • Managing dynamic learning systems post-approval
Health Data Records	• Unlocking value from unstructured data (e.g., clinical notes) • Improved data accuracy and integrity	• Navigating complex data privacy laws (HIPAA, GDPR, etc.) • Ensuring true anonymization and informed consent • Cybersecurity threats and breach mitigation • Poor data quality and lack of interoperability • Questions of data ownership and governance

Conclusion

The emergence of Artificial Intelligence (AI) in Digital Therapeutics (DTx) heralds a transformative era in healthcare, promising unprecedented personalization, efficiency, and accessibility in patient care. However, realizing this potential is contingent upon effectively navigating a complex and evolving regulatory landscape.

One of the primary challenges lies in the classification and categorization of AI-based DTx. Unlike traditional medical devices or pharmaceuticals, AI-driven solutions are dynamic, learning, and adapting over time. Existing regulatory frameworks often struggle to accommodate this inherent mutability, leading to ambiguities in how these solutions are defined, approved, and monitored. Should they be treated as software as a medical device (SaMD) with continuous updates, or do they require a more drug-like approval process based on specific indications and clinical trials? The lack of a standardized global regulatory pathway creates hurdles for developers seeking market entry and for healthcare providers seeking to integrate these innovations.

Further complicating matters is the critical issue of data governance, privacy, and security. AI models rely heavily on vast amounts of patient data for training and validation. Ensuring the ethical collection, secure storage, and appropriate

use of this highly sensitive information is paramount. Regulators face the challenge of establishing robust data protection laws that keep pace with technological advancements, addressing concerns around potential breaches, misuse of data, and the risk of algorithmic bias embedded within training datasets. This bias, if unchecked, can lead to discriminatory outcomes for certain patient populations, undermining the very goal of equitable healthcare.

The lack of clinical evidence and interoperability also poses significant regulatory challenges. As a relatively nascent field, AI-based DTx often lack the long-term clinical data that traditional treatments possess. Regulators need to define appropriate standards for evidence generation, balancing the need for rigorous validation with the rapid pace of technological innovation. Additionally, ensuring seamless integration of DTx with existing healthcare IT infrastructure and electronic health records is crucial for widespread adoption and effective patient management. Interoperability standards are still largely undefined, hindering the full potential of these solutions within integrated care pathways.

Moreover, there's a pressing need for regulatory agencies to enhance their capacity and capability. The complexity of AI systems demands specialized expertise in areas like machine learning, data science, and cybersecurity. Regulators must invest in training their staff, establishing dedicated AI-focused teams, and developing agile frameworks that can adapt to rapidly evolving technologies. Without this enhanced capacity, agencies risk becoming bottlenecks to innovation or, worse, failing to adequately protect public health and safety.

In conclusion, while AI-based DTx hold immense promise for revolutionizing healthcare, their effective and responsible integration hinges on overcoming significant regulatory hurdles. Future regulatory frameworks must be flexible, risk-proportionate, and globally harmonized. They need to address the unique characteristics of AI, including its dynamic nature, data dependencies, and the potential for bias. A collaborative approach involving regulators, developers, healthcare providers, and patients will be essential to establish clear guidelines, ensure patient safety, foster innovation, and ultimately unlock the full potential of AI-driven digital therapeutics to deliver truly personalized and effective healthcare solutions.

References

1. RAPS. (2024, September 18). The global regulatory landscape for AI/ML-enabled medical devices. RAPS. https://www.raps.org/News-and-Articles/News-Articles/2024/9/The-global-regulatory-landscape-for-AI-ML-enabled
2. FDA. (2025, March 25). Artificial Intelligence and Machine Learning in Software as a Medical Device. FDA. https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-software-medical-device
3. EY Global. How the challenge of regulating AI in healthcare is escalating. https://www.ey.com/en_gl/insights/law/how-the-challenge-of-regulating-ai-in-healthcare-is-escalating
4. European Parliament. (2025, February 19). EU AI Act: first regulation on artificial intelligence. https://www.europarl.europa.eu/topics/en/article/20230601STO93804/eu-ai-act-first-regulation-on-artificial-intelligence
5. AZoRobotics. (2025, February 26). The AI Regulatory Landscape in India: What to Know. https://www.azorobotics.com/Article.aspx?ArticleID=742
6. IBM. (n.d.). AI healthcare benefits. Retrieved from https://www.ibm.com/think/insights/ai-healthcare-benefits
7. Coursera. (n.d.). AI in Health Care: Applications, Benefits, and Examples. Retrieved from https://www.coursera.org/articles/ai-in-health-care
8. FDA. (2025, February 20). Artificial Intelligence for Drug Development. Retrieved from https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/artificial-intelligence-drug-development
9. Journal of Pharmaceutical & Industrial Research. (2025, January 12). Revolutionizing Healthcare: The Impact of AI on Precision Medicine. Retrieved from https://jpionline.org/10.5530/ijpi.20250100

10. ResearchGate. (2025, April 30). Ethical and Legal Challenges in the Use of Robotics for Critical Surgical Interventions. Retrieved from https://www.researchgate.net/publication/390673798_Ethical_and_Legal_Challenges_in_the_Use_of_Robotics_for_Critical_Surgical_Interventions
11. Baker McKenzie. (2023, October 27). Key considerations for regulation of artificial intelligence for health. Retrieved from https://connectontech.bakermckenzie.com/key-considerations-for-regulation-of-artificial-intelligence-for-health/
12. ICLG. (2025). Digital Health Laws and Regulations: Artificial Intelligence Tools in Health Services – An Overview of Current and Evolving US Federal and State Health Regulatory Structures 2025.
13. Innominds. (2025). Decoding Digital Therapeutics (DTx): A Powerful Tool for Patient-Centric Healthcare.
14. EY. (n.d.). How the challenge of regulating AI in healthcare is escalating.
15. The World Economic Forum. (2025). 6 ways AI is transforming healthcare.
16. Alation. (2025). Ethics of AI in Healthcare: Addressing Privacy, Bias & Trust in 2025.
17. Crisafulli, S., Santoro, E., Recchia, G., &Trifirò, G. (2022). Digital therapeutics in perspective: From regulatory challenges to post-marketing surveillance. Frontiers in Drug Safety and Regulation, 2, 900946.
18. Palanica, A., Docktor, M. J., Lieberman, M., &Fossat, Y. (2020). The need for artificial intelligence in digital therapeutics. Digital Biomarkers, 4(1), 21-25.
19. FDA. (2025). Artificial Intelligence and Machine Learning in Software as a Medical Device (SaMD) - Discussion Paper and Request for Feedback. (Note: This refers to the updated discussion paper based on search results).
20. European Commission. (2025). Artificial Intelligence in healthcare. (Information derived from recent EC publications).
21. Keragon. (2025). Regulation of AI in Healthcare: Guide for 2025. (Referenced for general regulatory landscape).
22. Pharmalex. (2025). The EU AI Act's impact on medical devices. (Referenced for EU AI Act specific impact).
23. Simq. (N.D.). The Challenges of Artificial Intelligence in Healthcare. (Referenced for ethical and trust factors).
24. Royal Society Publishing. (2025). Ethical and legal considerations in healthcare AI: innovation and policy for safe and fair use. (Referenced for bias mitigation strategies).
25. News-Medical.net. (2025). New guidelines to build trusted AI in healthcare research. (Referenced for FUTURE-AI guidelines).
26. "Revolutionizing precision oncology: the role of artificial intelligence in personalized pediatric cancer care." Frontiers in Medicine, May 2025.
27. "AI Enhancing Personalized Cancer Treatment." ICT&health Global, February 6, 2025.
28. "New AI approach enhances personalized medicine in cancer care." News-Medical.net, January 30, 2025.
29. "Artificial Intelligence (AI) and Cancer." National Cancer Institute, May 30, 2024.
30. "Current and Future Applications of AI in Cancer Treatment." Ezra, March 6, 2024.
31. "How AI and Genomics are Personalizing Cancer Treatment." USC Viterbi, February 28, 2025.
32. Crisafulli, S., Santoro, E., Recchia, G., &Trifirò, G. (2022). Digital therapeutics in perspective: From regulatory challenges to post-marketing surveillance. Frontiers in Drug Safety and Regulation, 2, 900946.
33. Birlasoft. (2024, February 12). Artificial Intelligence in Healthcare: Addressing Ethical and Regulatory Hurdles. Retrieved from https://www.birlasoft.com/articles/artificial-intelligence-in-healthcare-addressing-ethical-and-regulatory-hurdles
34. European Commission. (2025, March 5). Artificial Intelligence in healthcare. Retrieved from https://health.ec.europa.eu/ehealth-digital-health-and-care/artificial-intelligence-healthcare_en
35. MedPro Group. (n.d.). Artificial Intelligence in Healthcare: Challenges and Risks.

Retrieved from https://www.medpro.com/challenges-risks-artificial-intelligence
36. Meskó, B., &Gorcsan, P. (2020). The future of the physician-patient relationship in the artificial intelligence era. European Heart Journal, 41(2), 173-176.
37. Price, W. N., & Cohen, I. G. (2019). Artificial Intelligence in Health Care: The Future Is Now. AMA Journal of Ethics, 21(9), E764-E769.
38. Accenture. (2023). AI in Healthcare: The Future of Health. Retrieved from https://www.accenture.com/us-en/insights/life-sciences/ai-health
39. FDA. (2025, May 7). Artificial Intelligence and Machine Learning in Software as a Medical Device (SaMD). Retrieved from https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-software-medical-device-samd
40. Topchyan, A., &Pakhomov, S. (2022). The "black box" problem of AI in medicine: Exploring approaches to increase transparency. Journal of Medical Systems, 46(5), 1-8.
41. Forbes. (2024, October 8). Interoperability Challenges In Health Tech: The Gaps And Solutions. Retrieved from https://www.forbes.com/councils/forbestechcouncil/2024/10/08/interoperability-challenges-in-health-tech-the-gaps-and-solutions/
42. Accenture. (2023). AI in Healthcare: The Future of Health. Retrieved from https://www.accenture.com/us-en/insights/life-sciences/ai-health

Cite this article as:
Gupta G., Dwivedi A. and Darwhekar G.N. (2025). Digital Therapeutics: regulatory Challenges for AI-based Healthcare Solutions. *Int. J. of Pharm. & Life Sci.,* 16(10):7-20.

Source of Support: Nil
Conflict of Interest: Not declared
For reprints contact: ijplsjournal@gmail.com